| VHM Limited (VHM) ORDINARY FULLY PAID |
Materials |
$102 |
MOU with Currumbin Minerals for the Goschen Project
|
30 Apr 2025 8:30AM |
$0.310 |
$0.355 |
risen by
14.52%
|
|
| CurveBeam AI Limited (CVB) ORDINARY FULLY PAID |
Health Care |
$35 |
Investor Presentation - Q3 FY25 Quarterly Update
|
30 Apr 2025 8:30AM |
$0.095 |
$0.075 |
fallen by
21.05%
|
|
CVB - Price-sensitive ASX Announcement
Full Release
Key Points
- CurveBeam AI Limited operates in the orthopaedic imaging sector, specializing in weight-bearing CT technologies.
- The company serves markets in the U.S., Europe, and Asia-Pacific, with a focus on expanding its commercial footprint.
- Q3 FY25 saw revenue growth compared to previous quarters, driven by increased product adoption and market expansion.
- CurveBeam AI maintains a strong cash balance and continues to invest in R&D, sales, and marketing to support future growth.
- Recent milestones include key regulatory approvals, new product launches, and strategic partnerships with healthcare providers.
- The company highlights a significant market opportunity in musculoskeletal imaging as healthcare providers seek advanced diagnostic solutions.
- Management remains focused on executing the company’s growth strategy, leveraging proprietary technology and expanding its customer base.
- CurveBeam AI anticipates continued growth and innovation, supported by its experienced leadership team and industry partnerships.
- The Investor Presentation provides forward-looking statements regarding market expansion, product pipeline, and financial outlook.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| GreenTech Metals Limited (GRE) ORDINARY FULLY PAID |
Materials |
$13 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Apr 2025 8:30AM |
$0.045 |
$0.074 |
risen by
64.44%
|
|
GRE - Price-sensitive ASX Announcement
Full Release
Key Points
- Maiden JORC Mineral Resource Estimate completed for Whundo Project.
- Drilling at Ruth Well confirmed nickel-copper sulphide mineralisation.
- Geophysical and geochemical surveys undertaken to identify new targets.
- Advancements in asset acquisition and strategic partnerships.
- Progress in environmental and heritage surveys for project areas.
- Successful capital raising to fund ongoing exploration activities.
- Completion of exploration expenditures and reporting of cash flow in Appendix 5B.
- Focus on Western Australian battery metals projects.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NOVONIX Limited (NVX) ORDINARY FULLY PAID |
Information Technology |
$344 |
NOVONIX Finalises PSA for Enterprise South Land
|
30 Apr 2025 8:30AM |
$0.450 |
$0.410 |
fallen by
8.89%
|
|
NVX - Price-sensitive ASX Announcement
Full Release
Key Points
- NOVONIX Limited has finalised a Project Site Agreement (PSA) for the Enterprise South Industrial Park in Chattanooga, Tennessee.
- The PSA secures the location for a planned 30,000 tpa synthetic graphite anode material facility.
- This facility is integral to NOVONIX’s strategy for domestic battery material supply in North America.
- The agreement involves steps for site acquisition, development milestones, and coordination with local and state agencies.
- NOVONIX is advancing funding initiatives and regulatory processes to support project execution.
- The company is focused on serving the electric vehicle and energy storage sectors with US-made materials.
- The announcement highlights NOVONIX's commitment to sustainability and enhancing North American supply chain resilience.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Computershare Limited (CPU) ORDINARY FULLY PAID |
Industrials |
$19,607 |
Update - Notification of buy-back - CPU
|
30 Apr 2025 8:29AM |
$40.250 |
$33.900 |
fallen by
15.78%
|
|
| CurveBeam AI Limited (CVB) ORDINARY FULLY PAID |
Health Care |
$35 |
Quarterly Activity Report - Q3 FY25
|
30 Apr 2025 8:29AM |
$0.095 |
$0.075 |
fallen by
21.05%
|
|
CVB - Price-sensitive ASX Announcement
Full Release
Key Points
- Provided update on progress of clinical trials and regulatory milestones.
- Highlighted key commercial activities and expansion into new markets.
- Reported sales growth and interest in musculoskeletal CT imaging solutions.
- Outlined financial position including cash reserves and quarterly expenditures.
- Discussed ongoing product development and enhancement efforts.
- Described partnerships and collaborations to support growth.
- Mentioned regulatory submissions and approvals received in the quarter.
- Detailed upcoming business development and market expansion initiatives.
- Emphasized strengthening of product portfolio and market presence.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| CurveBeam AI Limited (CVB) ORDINARY FULLY PAID |
Health Care |
$35 |
Quarterly Appendix 4C Cash Flow Report
|
30 Apr 2025 8:29AM |
$0.095 |
$0.075 |
fallen by
21.05%
|
|
CVB - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly Appendix 4C Cash Flow Report released for the quarter ended 31 March 2024.
- Net cash outflows from operating activities due to research and development, staff costs, and administration expenses.
- Receipts from customers were recorded, but operating cash outflows led to negative net operational cash flow.
- Details of cash balances at the end of the quarter provided.
- Payments to related parties and associates disclosed.
- Report includes a compliance statement with ASX Listing Rules.
- Commentary on ongoing business activities, including research and commercialization of medical imaging products.
- Company outlines funding position and anticipated need for further funding for continued growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Tryptamine Therapeutics Limited (TYP) ORDINARY FULLY PAID |
Health Care |
$53 |
Quarterly Activities Report and Appendix 4C
|
30 Apr 2025 8:29AM |
$0.032 |
$0.034 |
risen by
6.25%
|
|
TYP - Price-sensitive ASX Announcement
Full Release
Key Points
- Completion of the first phase of Phase 2a clinical trial for treatment-resistant depression.
- Presentation of positive initial results from clinical trials.
- Ongoing engagement with regulatory agencies to support clinical programs.
- Development and expansion of intellectual property portfolio.
- Appendix 4C shows strong financial management and a solid cash position.
- Focus on clinical development, regulatory strategy, and operational execution.
- Commitment to delivering innovative psychedelic-assisted therapies.
- Proactive communication with stakeholders and market.
- No significant negative events or setbacks reported during the quarter.
- Company is well-positioned to achieve its near-term and long-term objectives.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Southern Palladium Limited (SPD) ORDINARY FULLY PAID |
Materials |
$208 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Apr 2025 8:29AM |
$0.225 |
$1.665 |
risen by
640%
|
|
SPD - Price-sensitive ASX Announcement
Full Release
Key Points
- Scoping Study for Bengwenyama PGM project completed, confirming robust project economics.
- Key drilling results received, supporting Mineral Resource estimates and potential project expansion.
- Community and environmental engagement activities continued, reinforcing SPD’s commitment to ESG principles.
- Preparations underway for a Pre-Feasibility Study scheduled for the coming quarters.
- Ongoing drilling programs focused on resource definition and exploration.
- Quarterly cash outflows were in line with expectations, and the company maintained a strong cash position.
- No significant production or revenue was reported, as the company remains in the exploration and development stage.
- No material changes in tenements or issued capital during the quarter.
- SPD continues to monitor and manage geopolitical and operational risks associated with South African projects.
- Financial and operational activities were detailed in the Appendix 5B Cash Flow Report, highlighting major expenditure categories.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Amplia Therapeutics Limited (ATX) ORDINARY FULLY PAID |
Health Care |
$62 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Apr 2025 8:28AM |
$0.053 |
$0.120 |
risen by
126.42%
|
|
ATX - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly Activities and Appendix 4C Cash Flow Report released for period ending 31 March 2024.
- Lead drug AMP945 in active Phase 2 clinical trial (ACCENT) for pancreatic cancer, with positive recruitment progress.
- Preparations ongoing for INSPIRE Phase 2 trial in idiopathic pulmonary fibrosis (IPF), with regulatory and site activation steps underway.
- Financially, Amplia completed a $6.8 million capital raise and ended the quarter with $10.1 million in cash.
- Expenditure focused on clinical trial activities, research, and operational support.
- No payments were made to related parties or their associates during the quarter.
- Strong engagement maintained with clinical partners, investigators, and global regulatory agencies.
- Company remains on track to meet clinical milestones and further development objectives in 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ecofibre Limited (EOF) ORDINARY FULLY PAID |
Health Care |
- |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Apr 2025 8:28AM |
$0.022 |
$0.020 |
fallen by
9.09%
|
|
| Perpetual Limited (PPT) ORDINARY FULLY PAID |
Financials |
$2,161 |
Ceasing to be a substantial holder
|
30 Apr 2025 8:28AM |
$16.310 |
$18.800 |
risen by
15.27%
|
|
| Sierra Nevada Gold Inc. (SNX) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Materials |
$7 |
Annual Report to Securityholders
|
30 Apr 2025 8:28AM |
$0.018 |
$0.034 |
risen by
88.89%
|
|
| Sierra Nevada Gold Inc. (SNX) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Materials |
$7 |
Notice of Annual General Meeting/Proxy Form
|
30 Apr 2025 8:28AM |
$0.018 |
$0.034 |
risen by
88.89%
|
|
| Matsa Resources Limited (MAT) ORDINARY FULLY PAID |
Materials |
$113 |
Secondary Trading Notice
|
30 Apr 2025 8:27AM |
$0.065 |
$0.120 |
risen by
84.62%
|
|
| Rio Tinto Limited (RIO) ORDINARY FULLY PAID |
Materials |
$52,490 |
Becoming a substantial holder
|
30 Apr 2025 8:27AM |
$116.560 |
$141.400 |
risen by
21.31%
|
|
| Matsa Resources Limited (MAT) ORDINARY FULLY PAID |
Materials |
$113 |
Application for quotation of securities - MAT
|
30 Apr 2025 8:27AM |
$0.065 |
$0.120 |
risen by
84.62%
|
|
| Bulletin Resources Limited (BNR) ORDINARY FULLY PAID |
Materials |
$17 |
Change of Director's Interest Notice
|
30 Apr 2025 8:27AM |
$0.068 |
$0.058 |
fallen by
14.71%
|
|
| Cadence Capital Limited (CDM) ORDINARY FULLY PAID |
Financials |
$209 |
Update - Notification of buy-back - CDM
|
30 Apr 2025 8:27AM |
$0.605 |
$0.700 |
risen by
15.70%
|
|
| MAAS Group Holdings Limited (MGH) ORDINARY FULLY PAID |
Industrials |
$1,652 |
Update - Notification of buy-back - MGH
|
30 Apr 2025 8:27AM |
$3.950 |
$4.540 |
risen by
14.94%
|
|
| Pancontinental Energy NL (PCL) ORDINARY FULLY PAID |
Energy |
$83 |
Quarterly Activities Report
|
30 Apr 2025 8:27AM |
$0.008 |
$0.010 |
risen by
25%
|
|
PCL - Price-sensitive ASX Announcement
Full Release
Key Points
- Pancontinental Energy NL focuses on oil and gas exploration in Namibia and Australia.
- Significant progress reported on Namibia’s PEL 87, including farm-out processes and partner engagement.
- PEL 37 in Namibia saw continued technical work and discussions with potential partners.
- In Western Australia, Pancontinental continues to progress exploration efforts in the Perth Basin.
- The company is actively interpreting new and existing seismic data to identify drilling targets.
- Financial summary provided, including exploration and corporate expenditure for the quarter.
- Pancontinental remains committed to unlocking the hydrocarbon potential of its Namibian licenses.
- No production or development occurred during the reporting period.
- Regulatory compliance and environmental considerations are ongoing components of their operations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pancontinental Energy NL (PCL) ORDINARY FULLY PAID |
Energy |
$83 |
Appendix 5B
|
30 Apr 2025 8:27AM |
$0.008 |
$0.010 |
risen by
25%
|
|
PCL - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly cash flow report (Appendix 5B) for period ended 31 March 2024 released
- Exploration and evaluation expenditure reported for the quarter
- Operating cash outflows mainly attributable to exploration activity and administration
- No receipts from product sales or customers during the quarter
- Investing cash flows primarily relate to payments for exploration and evaluation
- No significant inflows from financing activities during the quarter
- Cash at the end of the quarter disclosed in compliance with ASX requirements
- Commentary provided on major exploration projects and corporate activities
- Compliance statements included as required by ASX Listing Rules
- No payments made to related parties or their associates beyond disclosed directors’ fees
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Middle Island Resources Limited (MDI) ORDINARY FULLY PAID |
Materials |
$27 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Apr 2025 8:26AM |
$0.020 |
$0.027 |
risen by
35%
|
|
MDI - Price-sensitive ASX Announcement
Full Release
Key Points
- Middle Island Resources Limited (MDI) provided its quarterly report for the period ending 31 March 2023.
- The company continues to focus on its Barkly Copper-Gold Project located in the Northern Territory.
- Drilling programs at the Barkly Project were delayed due to weather but preparations for an upcoming campaign are underway.
- MDI is continuing data review and targeting activities to further refine exploration priorities.
- No mining or production activities were conducted during the quarter.
- The company did not make any significant acquisitions or disposals of tenements during the period.
- Expenditure for the quarter was primarily related to exploration and administration costs.
- MDI held a healthy cash balance at the end of the quarter, as detailed in their Appendix 5B cash flow report.
- There were no material changes in the business activities or capital structure of the company.
- MDI maintains a strong focus on exploration, stakeholder engagement, and compliance with regulatory obligations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Critical Resources Limited (CRR) ORDINARY FULLY PAID |
Materials |
$27 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Apr 2025 8:26AM |
$0.003 |
$0.009 |
risen by
200%
|
|
CRR - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly Activities and Appendix 5B Cash Flow Report released for period ending 31 December 2023
- Continued advancement of Mavis Lake Lithium Project in Ontario, Canada
- Ongoing drilling and resource expansion at Mavis Lake
- Identification of multiple new lithium pegmatite targets
- Progress on permitting and environmental baseline studies
- Active engagement with local communities and First Nations
- Cash flows reflect sustained investment in exploration and operations
- Maintained a healthy cash balance to support future activities
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Infini Resources Limited (I88) ORDINARY FULLY PAID |
Materials |
$20 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Apr 2025 8:26AM |
$0.100 |
$0.230 |
risen by
130%
|
|
I88 - Price-sensitive ASX Announcement
Full Release
Key Points
- Infini Resources Limited (ASX: I88) released its Quarterly Activities Report and Appendix 5B Cash Flow Report for the period ending 31 March 2024.
- Key activities included ongoing exploration across the company's portfolio of uranium and battery metals projects in Australia and Canada.
- The company highlighted progress at the Portland Creek Uranium Project in Newfoundland, Canada, with follow-up exploration work including field reconnaissance and geophysical interpretation.
- Infini advanced its Western Australian projects, notably the Yalgarra uranium-REE project and the Tambourah lithium project, including planning for upcoming exploration activities.
- A strategic review of all projects was undertaken to prioritize high-potential targets and allocate resources effectively.
- Corporate activities for the quarter included the completion of a placement raising $1.4 million before costs, strengthening the company’s cash position.
- The company ended the quarter with a strong financial position, reporting a cash balance of approximately $2.5 million.
- No production or revenues were recorded during the quarter as the company remains focused on exploration and project development.
- Infini continues to evaluate new opportunities within the uranium and battery minerals sector to enhance its project portfolio.
- The Appendix 5B Cash Flow Report details exploration expenditures, administration costs, and fundraising inflows for the quarter.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
